Physician profile
Sara West
NPI 1639382062
$8,390.58
in general payments reported to CMS, 2019-2025
16 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $238 · 2021: $1,455 · 2022: $1,102 · 2023: $2,019 · 2024: $1,662 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,286 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,285.81 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,694.31 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Alkermes, INC. | $1,268.92 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,177.50 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,017.29 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $822.48 | 2020-2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $607.34 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $588.61 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $518.95 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $259.84 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $170.35 | 2024-2025 | Fanapt |
| Indivior INC. | $158.95 | 2022-2025 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $37.79 | 2021 | |
| Braeburn INC. | $19.69 | 2024 | Brixadi |
| Axsome Therapeutics, INC. | $17.07 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $15.80 | 2024 | Secuado |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.69 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.